Last reviewed · How we verify

NCT06064318: EMKAR ONE

Prevalence and Incidence of Multiple Revisions Following Knee Arthroplasty in Denmark 1998-2021: A Nationwide Population-based Study

Completed Last updated 4 June 2025
What this trial tests

trial testing Revision in Knee Replacement in 161,384 participants. Completed in 1 April 2024.

Timeline
1 February 2023
Primary endpoint
2 September 2023
1 April 2024

Quick facts

Lead sponsorRigshospitalet, Denmark
StatusCompleted
Study typeOBSERVATIONAL
Enrollment161,384
Start date1 February 2023
Primary completion2 September 2023
Estimated completion1 April 2024
Sites1 location across Denmark

Drugs / interventions tested

Conditions studied

Sponsor

Rigshospitalet, Denmark

Who can join

Eligibility, any sex, with Knee Replacement or Knee Replacement Revision. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to investigate the incidence and prevalence rates of multiply revised knee arthroplasty patients in Denmark from 1998-2021.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Incidence and survival of multiply revised knee arthroplasties in Denmark 1998-2021: a nationwide register-based study.
    Hald JT, El-Galaly AB, Petersen MM, Lindberg-Larsen M, et al · · 2024 · cited 2× · PMID 39167020 · DOI 10.2340/17453674.2024.41257

Verify or expand the search:

Other recruiting trials for Knee Replacement

Currently open trials in the same condition.

Other Rigshospitalet, Denmark trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06064318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing